J&J Procrit Label Adds Warning On Treatment To High Hemoglobin Levels
This article was originally published in The Pink Sheet Daily
Executive Summary
The labeling change stems from a clinical trial of another erythropoietin product where increased mortality was observed in patients treated to high hemoglobin target levels. Amgen has included the information from the study in its label for Epogen.